Patents Assigned to Protarga, Inc.
-
Publication number: 20050004019Abstract: The invention relates to neuroprotective peptides which bind calcium and which are useful in treating stroke and other neurodegenerative diseases, as well as compositions containing such peptides. The peptides preferably are conjugated to or administered with a compound which facilitates delivery across the blood-brain barrier.Type: ApplicationFiled: September 29, 2003Publication date: January 6, 2005Applicant: Protarga, Inc.Inventor: Victor Shashoua
-
Publication number: 20040180949Abstract: The invention provides conjugates of cis-docosahexaenoic acid and pharmaceutical agents useful in treating noncentral nervous system conditions. Methods for selectively targeting pharmaceutical agents to desired tissues are provided.Type: ApplicationFiled: July 14, 2003Publication date: September 16, 2004Applicant: Protarga, Inc.Inventors: Victor E. Shashoua, Charles E. Swindell, Nigel L. Webb, Matthews O. Bradley
-
Patent number: 6627601Abstract: The invention relates to neuroprotective peptides which bind calcium and which are useful in treating stroke and other neurodegenerative diseases, as well as compositions containing such peptides. The peptides preferably are conjugated to or administered with a compound which facilitates delivery across the blood-brain barrier.Type: GrantFiled: March 16, 2001Date of Patent: September 30, 2003Assignee: Protarga, Inc.Inventor: Victor Shashoua
-
Patent number: 6602902Abstract: The invention provides conjugates of cis-docosahexaenoic acid and pharmaceutical agents useful in treating noncentral nervous system conditions. Methods for selectively targeting pharmaceutical agents to desired tissues are provided.Type: GrantFiled: May 1, 2001Date of Patent: August 5, 2003Assignee: Protarga, Inc.Inventors: Victor E. Shashoua, Charles E. Swindell, Nigel L. Webb, Matthews O. Bradley
-
Patent number: 6576636Abstract: The invention provides conjugates of fatty acids and antiviral agents useful in treating liver disorders.Type: GrantFiled: December 5, 2000Date of Patent: June 10, 2003Assignee: Protarga, Inc.Inventors: Nigel L. Webb, Matthews O. Bradley, Charles S. Swindell, Victor E. Shashoua
-
Patent number: 6407137Abstract: The invention involves the formation of a prodrug from a fatty acid carrier and a neuroactive drug. The prodrug is stable in the environment of both the stomach and the bloodstream and may be delivered by ingestion. The prodrug passes readily through the blood brain barrier. Once in the central nervous system, the prodrug is hydrolyzed into the fatty acid carrier and the drug to release the drug. In a preferred embodiment, the carrier is 4, 7, 10, 13, 16, 19 docosahexa-enoic acid and the drug is dopamine. Both are normal components of the central nervous system. The covalent bond between the drug and the carrier preferably is an amide bond, which bond may survive the conditions in the stomach. Thus, the prodrug may be ingested and will not be hydrolyzed completely into the carrier molecule and drug molecule in the stomach.Type: GrantFiled: July 9, 2001Date of Patent: June 18, 2002Assignee: Protarga, Inc.Inventor: Victor E. Shashoua
-
Patent number: 6258836Abstract: The invention involves the formation of a prodrug from a fatty acid carrier and a neuroactive drug. The prodrug is stable in the environment of both the stomach and the bloodstream and may be delivered by ingestion. The prodrug passes readily through the blood brain barrier. Once in the central nervous system, the prodrug is hydrolyzed into the fatty acid carrier and the drug to release the drug. In a preferred embodiment, the carrier is 4, 7, 10, 13, 16, 19 docosahexa-enoic acid and the drug is dopamine. Both are normal components of the central nervous system. The covalent bond between the drug and the carrier preferably is an amide bond, which bond may survive the conditions in the stomach. Thus, the prodrug may be ingested and will not be hydrolyzed completely into the carrier molecule and drug molecule in the stomach.Type: GrantFiled: November 29, 1999Date of Patent: July 10, 2001Assignee: Protarga, Inc.Inventor: Victor E. Shashoua
-
Patent number: 6225444Abstract: The invention relates to neuroprotective peptides which bind calcium and which are useful in treating stroke and other neurodegenerative diseases, as well as compositions containing such peptides. The peptides preferably are conjugated to or administered with a compound which facilitates delivery across the blood-brain barrier.Type: GrantFiled: February 10, 1998Date of Patent: May 1, 2001Assignee: Protarga, Inc.Inventor: Victor E. Shashoua
-
Patent number: 6197764Abstract: The invention provides compositions that include conjugates of a fatty acid molecule, preferably cis-docosahexaenoic acid, and clozapine. The conjugates are useful in treating psychological disorders such as schizophrenia.Type: GrantFiled: November 26, 1997Date of Patent: March 6, 2001Assignee: Protarga, Inc.Inventors: Matthews O. Bradley, Victor E. Shashoua, Charles S. Swindell, Nigel L. Webb
-
Patent number: 6153653Abstract: The invention provides compositions that include conjugates of choline and a fatty acid, preferably cis-docosahexaenoic acid. The conjugates are useful in treating disorders resulting from cerebral ischemia including stroke.Type: GrantFiled: November 26, 1997Date of Patent: November 28, 2000Assignee: Protarga, Inc.Inventor: Victor E. Shashoua